Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, completed a $34 million Series A financing round.
The company plans to use the proceeds to accelerate new research and development by adding scientists and expertise focused on emerging science, including regenerative medicine. It also plans to add to its intellectual property and patent portfolio and expand its laboratory, animal care, and advanced reproductive facilities. Finally, it will build out its business development, product marketing, and management team to take advantage of licensing and co-development opportunities. In conjunction with this financing, Recombinetics claims to have converted or repaid all of its outstanding debt.